Jennifer Doudna - Johnson Johnson Independent Director

<div class='circular--portrait' style='background:#FF6600;color: white;font-size:3em;padding-top: 40px;;'>JNJ</div>
JNJ -- USA Stock  

Fiscal Quarter End: March 31, 2020  

Dr. Jennifer A Doudna, Ph.D., is the Independent Director of the Company. She has joined the faculty at University of California, Berkeley, as a Professor of Biochemistry Molecular Biology in 2002. She directs the Innovative Genomics Institute, a joint UC BerkeleyUC San Francisco center, holds the Li Ka Shing Chancellors Professorship in Biomedicine and Health, and is the chair of the Chancellors Advisory Committee on Biology at UC Berkeley. Dr. Doudna is Principal Investigator at the Doudna Lab at UC Berkeley and has founded and serves on the scientific advisory boards of Caribou Biosciences, Inc. and Intellia Therapeutics, Inc., both leading CRISPR genome engineering companies. She was an Investigator with the Howard Hughes Medical Institute since 1997. Dr. Doudna is the recipient of numerous scientific awards in biochemistry and genetics, including the Alan T. Waterman Award the Eli Lilly Award in Biological Chemistry of the American Chemical Society a corecipient of the Breakthrough Prize in Life Sciences a corecipient of the Gruber Prize in Genetics a corecipient of the Canada Gairdner International Award the Heineken Prize for Biochemistry and Biophysics the Tang Prize the Japan Prize and the Albany Medical Center Prize . Dr. Doudna was elected to the National Academy of Sciences the American Academy of Arts and Sciences the National Academy of Medicine the National Academy of Inventors and as a Foreign Member of the Royal Society . Dr. Doudna is a Trustee for Pomona College.
Age: 54  Director Since 2018      
732 214-0332  www.jnj.com

Management Efficiency

The company has 30.43 B in debt with debt to equity (D/E) ratio of 50.0 . This implies that the company may be unable to create cash to meet all of its financial commitments. Johnson Johnson has Current Ratio of 1.3 demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives


Patrick OSullivanAllergan Plc
Daniel PodolskyGlaxoSmithKline PLC
Alan LacyBristol Myers Squibb Company
Dimitri AzarNovartis AG
Peter McDonnellAllergan Plc
Don CornwellPfizer
Scott GottliebPfizer
Harish ManwaniGilead Sciences
Tony MokAstrazeneca PLC
Jose BaselgaBristol Myers Squibb Company
Christopher BodineAllergan Plc
Juan LucianoEli Lilly And Company
Robert KidderMerck Company
Hans WijersGlaxoSmithKline PLC
William HarrisonMerck Company
Helen HobbsPfizer
Togo WestBristol Myers Squibb Company
Karen HornEli Lilly And Company
Peter WendellMerck Company
Weiying WangAstrazeneca PLC
Marcus WallenbergAstrazeneca PLC

Company Summary

Johnson Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. The company was incorporated in 1887 and is based in New Brunswick, New Jersey. Johnson Johnson operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange.Johnson Johnson (JNJ) is traded on BATS Exchange in USA. It is located in One Johnson and Johnson Plaza, New Brunswick, NJ 08933, United States and employs 135,100 people. Johnson Johnson is listed under Pharmaceutical Products category by Fama And French industry classification.

Johnson Johnson Leadership Team

A Washington, Independent DirectorView
Jennifer Doudna, Independent DirectorView
Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. CommitteeView
William Perez, Independent DirectorView
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication OfficerView
Marillyn Hewson, Independent DirectorView
Jorge Mesquita, Executive Vice President Worldwide Chairman - ConsumerView
Mary Coleman, Independent DirectorView
Michael Ullmann, VP, General Counsel and Member of Executive CommitteeView
Joaquin Duato, Executive Vice President Worldwide Chairman - PharmaceuticalsView
Kathy Wengel, Executive Vice President Chief Global Supply Chain OfficerView
Jennifer Taubert, Executive Vice President - Worldwide Chairman, PharmaceuticalsView
Mary Beckerle, Independent DirectorView
Sandra Peterson, Group Worldwide Chairman and Member of Executive CommitteeView
Scott Davis, DirectorView
Louise Mehrotra, Vice President Investor RelationsView
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical DevicesView
Ronald Williams, Independent DirectorView
Kathryn Wengel, Executive Vice President Chief Global Supply Chain OfficerView
D Davis, Independent DirectorView
Hubert Joly, DirectorView
Anne Mulcahy, Lead Independent DirectorView
Joseph Wolk, Chief Financial Officer, Executive Vice PresidentView
Thibaut Mongon, Executive Vice President Worldwide Chairman, ConsumerView
Ian Davis, Independent DirectorView
Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive CommitteeView
Mark McClellan, Independent DirectorView
Charles Prince, Independent DirectorView
Eugene Washington, Independent DirectorView
Dominic Caruso, CFO, VP of Fin. and Member of Executive CommitteeView
Peter Fasolo, Chief Human Resource Officer, Executive Vice PresidentView
Susan Lindquist, Independent DirectorView
Mark Weinberger, DirectorView

Stock Performance Indicators

Did you try this?

Run Stock Tickers Now


Stock Tickers

Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. Please also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.